We're studying if a new weight loss drug can help people on buprenorphine reduce their opioid use

RENEW is a study to learn more about brenipatide, a possible new treatment to help people stop using opioids.

The intervention is a new weight loss drug, brenipatide, combined with existing buprenorphine or buprenorphine and naloxone. 

To see if you may be eligible to participate, call us at 628-217-6325 or send us your contact information using the contact form on this page. Someone from our team will contact you to see if you may be eligible to come into our office. If you are, we will set up your first screening visit. 

Screening includes meeting with a research associate, clinical staff and various other procedures. This will be explained to you during the informed consent process. 

The screening process can take up to 4-5 weeks to determine if you are eligible to participate.   

 If you are eligible and choose to participate, you will be asked to attend about 1 visit each week for 56-144 weeks. The visits will occur at our office at Market St. and Van Ness in San Francisco.

Yes! Your time and contribution are of tremendous value to public health research. 

If you are eligible, you can earn up to $7,130 for completing all study activities and 

procedures.